Platforms aid pancreatic cancer patients and specialists
China’s first registration platform for patients in late pancreatic cancer was launched in the China Pancreatic Oncology Conference in the city on Saturday.
A new Internet-based pancreatic cancer group consulting platform was also announced.
“Two platforms, with participation of some 30 hospitals, will help achieve a more balanced medical capability,” said Dr Wang Liwei from Renji Hospital and director of pancreatic cancer branch of Chinese Medical Association.
The registration platform will hold medical records, effects of treatment and survival rates, providing data for clinical research and regulating medical practice across regions.
The consulting platform will gather specialists to offer consultation for patients, who need no longer go all the way to big cities.
The incidence of pancreatic cancer is rising in China, with about 90,000 new patients every year. Pancreatic cancer is one of the cancers with the highest mortality and shortest survival. It is difficult to detect in the early stages, so about 60 percent of patients are already in the terminal stage when confirmed with cancer. Only 15 percent of patients have the chance of surgery upon diagnosis.